Angiogenesis: Molecular Pathways, Clinical Challenges, and Emerging Therapies

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a fundamental biological process occurring throughout life, from embryonic development to tissue maintenance and repair in adulthood. No metabolically active tissue lies more than a few hundred micrometers from a blood capillary, emphasizing the critical role of angiogenesis in sustaining cellular viability. Over the past four decades, the recognition of angiogenesis as a pivotal player in both physiological and pathological processes has garnered considerable therapeutic interest. Under physiological conditions, angiogenesis facilitates growth, wound healing, and tissue regeneration. Conversely, its dysregulation is implicated in numerous pathological states, including cancer, cardiovascular diseases, diabetic retinopathy, and rheumatoid arthritis. The dual nature of angiogenesis, as both a restorative and a pathological mechanism, has made it a compelling target for therapeutic intervention. While inhibition of angiogenesis, particularly via vascular endothelial growth factor (VEGF) antagonists, has yielded promising outcomes in slowing tumor progression, limitations such as therapeutic resistance and limited survival benefits persist. Future directions are increasingly focused on combinatorial approaches that integrate anti-angiogenic agents with immunotherapies to enhance clinical efficacy. Conversely, therapeutic stimulation of angiogenesis offers hope in regenerative medicine, particularly for treating ischemic conditions and enhancing tissue repair. Emerging technologies such as nanomedicine and novel targeting of alternative angiogenic pathways are opening new frontiers for precise and individualized therapies. This review aims to comprehensively explore the dual role of angiogenesis in health and disease, highlighting its therapeutic potential in both regenerative medicine and oncology. It discusses current anti- and pro-angiogenic strategies, key molecular targets, limitations of existing therapies, and innovative future approaches, including combination regimens and nanotechnology-driven interventions.